格隆汇2月9日｜Argus Research将安进的目标价从360美元上调至400美元，维持"买入"评级。(格隆汇) ...

The Dow surged 1,206.95 points, or 2.47%, to close at 50,115.67, outperforming the broader market. For the year so far, the index is up about 4.3%, compared with gains of 1.3% for the S&P 500 and a decline of around 0.9% for the Broadening Beyond Big TechA key driver behind the Dow’s move to 50,000 has been a broadening of market leadership beyond a narrow group of mega-cap technology and artificial intelligence stocks. Investors have increasingly rotated into economically sensitive and value-oriented sect ...

Market Overview - The Dow Jones Industrial Average surged above 50,000 points for the first time, closing at 50,115.67, up more than 1,200 points or 2.5 percent, reflecting a broadening market and confidence in growth stories [2][13] - The index has shown steady growth over the past two and a half years, with notable exceptions during specific political events [8][13] Company News - Amazon was the biggest loser on the Dow, falling 5.6 percent after announcing a $200 billion capital spending plan for AI capabilities in 2026, raising concerns about potential returns on such massive investments [5][13] - Other companies like Caterpillar, 3M, JPMorgan Chase, Goldman Sachs, Amgen, and Nvidia saw gains of at least four percent, indicating positive market sentiment towards their performance [5][13] - Stellantis shares plunged over 24 percent after announcing a €22 billion ($26 billion) write-down due to misjudging the shift to electric vehicles, with shares down around 80 percent over the past two years [9][13] - Rio Tinto's shares finished flat after dropping merger talks with Glencore, which would have created a $260 billion mining firm, while Glencore's stock climbed 1.5 percent [10][13] - Toyota's shares increased by two percent after raising profit and sales forecasts for the current fiscal year despite US tariffs [11][13] Investment Insights - Analysts suggest that the massive investments in AI by companies like Amazon will benefit infrastructure, banking, and other sectors, indicating a ripple effect across the market [5][6] - Confidence in earnings growth is noted, with expectations that equity investors will be rewarded, although volatility is anticipated [6][13]

Bolvin Wealth Management Group总裁Gina Bolvin表示，道指突破5万点"与其说是庆祝，不如说是一次确 认"。她指出，市场已经适应了更高利率、更慢的增长节奏以及全球不确定性，却仍能继续走高，这表 明投资者信心真实存在，2026年的市场焦点将更多回归企业基本面，而非货币政策。 智通财经APP获悉，周五，美股全面走强，道琼斯工业平均指数大涨逾1200点，涨幅约2.5%，盘中首次 突破5万点整数关口，收报50,115.67点，创下历史新高。 自2025年底以来，美股涨势逐步由科技板块向更广泛领域扩散，这一趋势显著利好道指成分股。尽管道 指同样包含英伟达(NVDA.US)、苹果(AAPL.US)和微软(MSFT.US)等科技巨头，今年推动指数上行的主 力，更多来自传统行业与防御型板块。其中，高盛(GS.US)、卡特彼勒(CAT.US)、安进(AMGN.US)以及 宣伟公司(SHW.US)等表现尤为突出。 由于道指采用价格加权方式计算，这些股价较高的成分股，对指数的影响力明显高于按市值加权的指 数。此外，波音近期股价同样持续走强，也对道指形成支撑。 回顾走势，自2024年5月首次站上4 ...

U.S. equities experienced a challenging day on Thursday, February 5, 2026, as a significant sell-off in technology stocks and discouraging reports from the job market weighed heavily on investor sentiment. The tech-heavy Nasdaq Composite (NDAQ) and the benchmark S&P 500 (SPX) both closed sharply lower, marking their third consecutive day of losses, while the Dow Jones Industrial Average (DJIA) also retreated amidst a broad "risk-off" environment.The S&P 500 fell 1.2% to close at 6,798.40, recording its sixt ...

Amgen Inc. (NASDAQ:AMGN) is included among the 15 Best Wide Moat Dividend Stocks to Invest in. RBC Lifts Amgen (AMGN) Target After Strong Q4, Cites Key Drug Momentum On February 4, RBC Capital raised its price recommendation on Amgen Inc. (NASDAQ:AMGN) to $360 from $335. The firm also kept an Outperform rating and pointed to a strong fourth quarter on both revenue and earnings. According to the research note, the upside was largely driven by Prolia, Repatha, Evenity, and Uplizna. On MariTide, Amgen did n ...

CVS Health said on Thursday it would swap out Amgen and Eli Lilly's bone disease treatments for lower-cost alternatives in some of its preferred drug lists, starting April 1. ...

During the first half of 2025, Wegovy and Zepbound, two weight loss drugs, ranked among the top 10 best-selling medicines worldwide. And given current projections for this market, we could see more weight management therapies among the top-selling drugs in the next five years. Two companies inching closer to launching anti-obesity medicines are Amgen (NASDAQ: AMGN) and Roche (OTC: RHHB.Y). Should investors consider purchasing shares of these leading drugmakers? Image source: Getty Images. 1. Amgen Amge ...

Market Analysis by covering: Amgen Inc. Read 's Market Analysis on Investing.com ...

花旗将安进的目标价从315美元上调至345美元，维持"中性"评级。(格隆汇) ...